Regulatory Expertise Pace Life Sciences operates within BioPharma Global, a regulatory affairs specialist focused on orphan drugs and expedited programs for US and EU markets. This positions the company to partner with biotech firms seeking FDA/EMA designations, RMAT, EMA PRIME, and FDA/EMA meetings to accelerate development timelines.

Rare Disease Focus The firm specializes in high unmet medical need areas including rare diseases, offering services from designation to regulatory strategy and IND filings. This creates opportunities to engage sponsors with orphan drug candidates seeking accelerated pathways and global regulatory alignment.

Global Regulatory Network With experience across FDA and EMA processes and a team including former FDA staff, BioPharma Global can serve as a gateway for sponsors aiming to navigate cross‑border submissions, meetings, and expedited programs, potentially reducing cycle times and compliance risk.

Proven Outcomes Historical milestones such as orphan drug designations and collaborations with regulatory authorities suggest a track record that can bolster a sponsor’s confidence when outsourcing regulatory affairs, integration into development timelines, and strategic planning.

Growth Opportunities Despite a small internal size, the company’s services and milestones indicate potential for strategic partnerships, co‑development or outsourcing arrangements with larger CROs or pharma groups seeking regulatory acceleration for multiple candidates across US and EU markets.